<DOC>
	<DOCNO>NCT00077493</DOCNO>
	<brief_summary>RATIONALE : BL22 immunotoxin locate tumor cell kill without harm normal cell . BL22 immunotoxin may effective treat relapsed refractory acute lymphoblastic leukemia non-Hodgkin 's lymphoma . PURPOSE : This phase I trial study side effect best dose BL22 immunotoxin treat young patient relapse refractory acute lymphoblastic leukemia non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>BL22 Immunotoxin In Treating Young Patients With Relapsed Refractory Acute Lymphoblastic Leukemia Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxic effect BL22 immunotoxin pediatric patient relapse refractory CD22-positive acute lymphoblastic leukemia non-Hodgkin 's lymphoma . - Determine maximum tolerate dose drug patient . - Determine immunogenicity drug patient . - Determine pharmacokinetics drug patient . Secondary - Determine vitro cytotoxicity drug lymphoblasts patient acute lymphoblastic leukemia . - Determine therapeutic efficacy drug induce remission patient . - Determine change lymphocyte subset , immunoglobulin level , serum cytokine , soluble cytokine receptor level patient treat drug . OUTLINE : This non-randomized , dose-escalation study . Patients receive BL22 immunotoxin IV 30 minute day 1 , 3 , 5 OR day 1 , 3 , 5 , 7 , 9 , 11 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) unconfirmed CR ( CRu ) receive 2 additional course beyond CR CRu maximum 6 course . Cohorts 3-6 patient receive escalate dos BL22 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , cohort expand total 12 patient treat dose . Patients follow weekly least 1 month every 1-3 month thereafter . PROJECTED ACCRUAL : A total 95 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) nonHodgkin 's lymphoma ( include lymphoblastic lymphoma , Burkitt 's lymphoma , large cell lymphoma ) Not amenable available curative therapy Relapsed refractory disease least 1 standard chemotherapy 1 salvage regimen CD22 positive accord least 1 follow criterion : More 15 % CD22positive malignant cell immunohistochemistry More 30 % CD22positive malignant cell fluorescentactivated cell sorter analysis Measurable evaluable disease Prior CNS involvement allow provide current evidence CNS malignancy No CNS leukemia lymphoma manifest following : Cerebrospinal fluid ( CSF ) WBC ≥ 5/mm^3 confirmation CSF blast Cranial neuropathy secondary underlying malignancy Radiologically detect CNS lymphoma No isolated testicular ALL Ineligible refuse hematopoietic stem cell transplantation OR disease activity prohibit time require identify suitable stem cell donor PATIENT CHARACTERISTICS : Age 6 month 24 year Performance status ECOG 03 ( 12 24 year age ) Lansky 40100 % ( 12 year age ) Life expectancy Not specify Hematopoietic See Disease Characteristics Absolute neutrophil count &gt; 1,000/mm^3 * Platelet count &gt; 50,000/mm^3 * NOTE : *Nonleukemic patient Hepatic Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 5 time upper limit normal No active hepatitis B C infection Renal Creatinine normal age OR Creatinine clearance ≥ 60 mL/min Immunologic No serum neutralization 75 % activity 1 µg/mL study drug HIV negative Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinically significant unrelated systemic illness would preclude study participation No significant organ dysfunction would preclude study participation No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 1 week since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) Prior autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) allow More 100 day since prior allogeneic HSCT Chemotherapy See Disease Characteristics At least 2 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy Concurrent corticosteroid allow provided increase dose 1 week prior study entry Steroid taper allow Radiotherapy At least 3 week since prior radiotherapy Allowed past 3 week provide volume bone marrow treat &lt; 10 % AND patient measurable disease outside radiation port Surgery Not specify Other Recovered prior therapy At least 30 day since prior investigational drug No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood non-Hodgkin lymphoma</keyword>
</DOC>